SG11202108276RA - Inhibiting or alleviating agent for inflammation in the brain - Google Patents

Inhibiting or alleviating agent for inflammation in the brain

Info

Publication number
SG11202108276RA
SG11202108276RA SG11202108276RA SG11202108276RA SG11202108276RA SG 11202108276R A SG11202108276R A SG 11202108276RA SG 11202108276R A SG11202108276R A SG 11202108276RA SG 11202108276R A SG11202108276R A SG 11202108276RA SG 11202108276R A SG11202108276R A SG 11202108276RA
Authority
SG
Singapore
Prior art keywords
inflammation
brain
inhibiting
alleviating agent
alleviating
Prior art date
Application number
SG11202108276RA
Inventor
Jun Liu
Wang Liao
Wenli Fang
Shengnuo Fan
Yuqiu Zheng
Original Assignee
Jun Liu
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jun Liu, Nippon Zoki Pharmaceutical Co filed Critical Jun Liu
Publication of SG11202108276RA publication Critical patent/SG11202108276RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
SG11202108276RA 2019-01-30 2019-01-30 Inhibiting or alleviating agent for inflammation in the brain SG11202108276RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/073846 WO2020154941A1 (en) 2019-01-30 2019-01-30 Inhibiting or alleviating agent for inflammation in the brain

Publications (1)

Publication Number Publication Date
SG11202108276RA true SG11202108276RA (en) 2021-08-30

Family

ID=71841719

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108276RA SG11202108276RA (en) 2019-01-30 2019-01-30 Inhibiting or alleviating agent for inflammation in the brain

Country Status (10)

Country Link
US (1) US20220096561A1 (en)
EP (1) EP3918335A4 (en)
JP (2) JP2022521125A (en)
KR (1) KR20210119974A (en)
CN (1) CN113424063A (en)
AU (1) AU2019426246A1 (en)
CA (1) CA3128060A1 (en)
IL (1) IL285211A (en)
SG (1) SG11202108276RA (en)
WO (1) WO2020154941A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022174378A1 (en) * 2021-02-19 2022-08-25 骏运投资有限公司 Use of extract from rabbit skin inflamed by vaccinia virus in treatment of demyelinating disease of nervous system
WO2023184470A1 (en) * 2022-04-01 2023-10-05 星相生物技术有限公司 Use of extracts from rabbit skin inflamed by vaccinia virus in treatment of alzheimer's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2539665B2 (en) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 Neurological drug
US6717031B2 (en) * 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20050287158A1 (en) * 2002-02-15 2005-12-29 Georgetown University The p65 subunit of nf-kb for the radiosensitization of cells
US7148012B2 (en) * 2002-10-31 2006-12-12 Nippon Zoki Pharmaceutical Co., Ltd. Therapeutic agent for fibromyalgia
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
EP1682171A4 (en) * 2003-11-07 2008-02-27 Univ Rochester Compositions and methods of treating neurological diseases
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
CN101802182A (en) * 2007-08-21 2010-08-11 诺达利蒂公司 Be used to diagnose, the method for prognosis and methods of treatment
EP2587265B1 (en) * 2010-06-25 2016-05-04 Nippon Zoki Pharmaceutical Co., Ltd. Method for determination or evaluation of test substance
US20150344535A1 (en) * 2012-09-28 2015-12-03 The University Of Queensland Neurotrophin-tyrosine kinase receptor signaling
JP5275502B1 (en) * 2012-10-10 2013-08-28 日本臓器製薬株式会社 Extracts and formulations
CN113893327A (en) * 2015-04-16 2022-01-07 首创生物药品发展有限公司 Therapeutic peptides for cerebrovascular diseases
WO2017066434A1 (en) * 2015-10-14 2017-04-20 The Trustees Of Columbia University In The City Of New York Brain-derived neurotrophic factor (bdnf)-tropomyosine kinase b (trkb) inhibition for improving cognitive deficits
JP7039468B2 (en) * 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Binding agonists for the treatment of nerve and other disorders
CN110381966A (en) * 2017-03-06 2019-10-25 刘军 The inhibition of A β-induction damage mitigates medicament
JP6607655B1 (en) * 2017-12-28 2019-11-20 学校法人兵庫医科大学 Lipocalin-type prostaglandin D2 synthase production promoter

Also Published As

Publication number Publication date
EP3918335A1 (en) 2021-12-08
AU2019426246A1 (en) 2021-08-19
EP3918335A4 (en) 2022-09-28
KR20210119974A (en) 2021-10-06
JP2022521125A (en) 2022-04-06
US20220096561A1 (en) 2022-03-31
CA3128060A1 (en) 2020-08-06
IL285211A (en) 2021-09-30
WO2020154941A1 (en) 2020-08-06
CN113424063A (en) 2021-09-21
JP2023065364A (en) 2023-05-12

Similar Documents

Publication Publication Date Title
IL278155B (en) Compounds and their uses for alleviating menopause-associated symptoms
IL278156A (en) Compounds and their uses for alleviating menopause-associated symptoms
HUE056356T2 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
EP3677265A4 (en) Composition for preventing or treating sleep disorders
HRP20190328T1 (en) Composition for topical application in the auditory canal
EP3508212A4 (en) Agent for regenerating visual function or agent for preventing deterioration in visual function
IL271884A (en) Compounds for the reducing lipotoxic damage
GB201902241D0 (en) Manufacturing system for use in space
IL285211A (en) Inhibiting or alleviating agent for inflammation of the brain
IL268090A (en) Inhibiting or alleviating agent for aß- induced damage
IL274378A (en) Phosphorylcholine-tuftsin conjugate for treating ocular inflammation
GB202214988D0 (en) Compositions and methods for preventing or treating nephrolithiasis
EP3533471A4 (en) Composition for alleviating or treating pain
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL286533A (en) Compounds for use in the treatment of adcy5-related dyskinesia
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL276641A (en) Cd59 for inhibiting inflammasome activation
GB2581876B (en) Compositions for use in the treatment of endometrial disorder
EP3710003A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING Beta- -GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3781171T (en) Compounds and their uses for alleviating menopause-associated symptoms
GB201820630D0 (en) Anti snore system
EP3713604C0 (en) Compound for use in the increasing of mental capability
EP3761971A4 (en) Compositions and methods for inhibiting inflammation
AU2018904524A0 (en) Inhibiting inflammation